At present, major listed pharmaceutical companies have disclosed their interim reports, and the business income of each enterprise has also surfaced
.
Judging from the publicly disclosed data, the hematopoiesis of innovative drugs is accelerating the transformation of traditional pharmaceutical companies and ushering in new growth in
performance.
For example, the performance of Yiling Pharmaceutical in the first half of 2022 shows that the operating income is 5.
566 billion yuan; Net profit attributable to the mother was 1.
049 billion yuan, an increase of 8.
76%
year-on-year.
Among them, continuous investment in research and development has obviously injected impetus
into the subsequent performance growth of Yiling Pharmaceutical.
Specifically, the semi-annual report shows that in the first half of this year, Yiling Pharmaceutical invested 385 million yuan in research and development, accounting for 6.
91%
of operating income.
By continuously increasing R&D efforts, Yiling Pharmaceutical has actively carried out new drug research and development in the fields of cardiovascular and cerebrovascular system diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other clinical and major diseases, and some innovative achievements have also entered the harvest period
.
It is understood that as of now, Yiling Pharmaceutical has been approved for 13 patented new drugs, including macaroni capsules/tablets, ginseng pine nourishing heart capsules, Qi Xiang Qiang Xin capsules, Lianhua Qingxiao capsules / granules / tablets, Jinlida granules, Yangzheng elimination capsules, Xia Liqi capsules, Lianhua cough tablets, anti-depression and annoyance capsules, beneficial kidney nourishing heart and mind relief tablets, etc
.
Among them, in 2021, in China's three major terminal 6 major markets, the cumulative sales of three proprietary Chinese medicines of Yiling Pharmaceutical, Lianhua Qingfeng, Macaroni Capsules and Ginseng Song Yangxin Capsules have approached 10 billion yuan
.
In addition, the total sales scale of Qi Qi Qiang Xin Capsules in China's three major terminal markets in 2021 also exceeded 900 million yuan, an increase of 48.
14%
year-on-year.
In addition to the development of innovative drugs, Yiling Pharmaceutical is also actively laying out chemical drugs, biological drugs and health industries, of which in the field of chemical innovative drugs, 4 Class 1 new drugs have entered the clinical stage; In terms of chemical generic drugs, 13 varieties of Yiling Pharmaceutical have passed or are deemed to have passed the consistency evaluation
.
The industry expects that if these products are successfully listed in the future, they will further enrich the company's product line, and are also expected to bring more new growth points
to the company's performance.
After many years of time, Hansen Pharmaceutical has begun to achieve remarkable results
in innovation.
According to statistics, since 2019, Hansen has a total of 5 innovative drugs approved, of which 4 are self-developed, namely polyethylene glycol lothenatide, flumartinib, ametinib, empirinofovir, and 1 is an imported drug, namely ineralizumab
.
Four self-developed innovative drugs and the company's listed sodium morphinazole in 2014 have brought a strong driving force
to the growth of Hansen's performance at this stage.
According to the semi-annual report of 2022, in the first half of the year, the company's innovative drug revenue was about 2.
321 billion yuan, an increase of about 84.
8% year-on-year, and the proportion of innovative drugs in revenue increased significantly to about 52.
3%, a new high, 28.
5%
in the same period last year.
Judging from the data of Hansen Pharmaceutical in the past three years, its innovative drug revenue has increased from 752 million yuan in H1 in 2020 to 2.
321 billion yuan in H1 in 2022, with a compound annual growth rate of 75.
68% during the period; The proportion of innovative drug revenue also increased from 18.
9% to 52.
3%.
In terms of R&D investment, Hengrui Pharmaceutical has actually been in the forefront, and in the past ten years, its cumulative R&D investment has reached 23.
8 billion yuan.
At present, under the continuous high R&D investment, the innovative achievements of Hengrui Pharmaceutical have also been highlighted and are ushering in a harvest period
.
According to statistics, since 2011, the company's innovative drugs have reached 11, including raviglutamide tablets, proline constant pagliflozin tablets, rimazoram toluenesulfonate for injection, carilizumab for injection, pirolitinib maleate tablets, and thiopeptograstim injection
.
In addition, more than 60 innovative drugs are under clinical development, and more than 250 clinical trials have been carried out at home and abroad, forming a rich product pipeline
of echelonization.
Industry insiders believe that at present, a large number of enterprise products that have laid out innovative drugs are gradually landing and entering the return period, and companies that already have innovative drug products or related business layouts in the future are expected to show strong competitiveness and growth potential
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
